Table 1 Patient characteristics
From: High-dose thiotepa-related neurotoxicity and the role of tramadol in children
|  | Patients (N = 251) |
|---|---|
Gender | |
 Boys | 145 (58%) |
 Girls | 106 (43%) |
Age (years; median [IQR]) | 8 [5–15] |
Race | Â |
 Caucasian | 186 (74%) |
 African | 40 (16%) |
 Others | 25 (10%) |
Brain tumour | 116 (46%) |
 Medulloblastoma | 71 (28%) |
 PNETa | 26 (10%) |
 Pinealoblastoma | 13 (5%) |
 ATRTb | 5 (2%) |
 Malignant GCTc | 1 (0.4%) |
Other tumour site | 135 (54%) |
 Osteosarcoma | 50 (20%) |
 Neuroblastoma | 26 (10%) |
 Ewing tumor | 23 (9%) |
 Rhabdomyosarcoma | 20 (8%) |
 Other sarcoma | 4 (2%) |
 Nephroblastoma | 4 (2%) |
 Burkitt lymphoma | 4 (2%) |
 Hepatoblastoma | 2 (1%) |
 Desmoplastic tumour | 2 (1%) |
Neurological disorder at baselined | 20 (8%) |
History of seizure | 13 (5%) |
Thiotepa dose | |
 600 mg/m2 | 129 (51%) |
 720 mg/m2 | 76 (30%) |
 900 mg/m2 | 46 (18%) |
Concomitant drugse | |
 Alizapride | 94 (43%) |
 Antibiotic | 49 (22%) |
 Antidepressant | 7 (3%) |
 Antipsychotic | 40 (18%) |
 Aprepitant | 7 (3%) |
 Benzodiazepine | 43 (20%) |
 Histamine H2-receptor antagonist | 5 (2%) |
 Proton Pump Inhibitor | 7 (3%) |
Analgesics | 92 (42%) |
 Simple analgesics | 76 (35%) |
 i.e. acetaminophen, nefopam |  |
 Weak opioids | 53 (24%) |
 i.e. tramadol, codeine, dextropropoxyphen |  |
 Strong opioids | 9 (4%) |
 i.e. morphine, pethidine |  |